Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers

Weiwei Feng, Rosaria Orlandi, Naiqing Zhao, Maria L. Carcangiu, Elda Tagliabue, Jia Xu, Robert C. Bast, Yinhua Yu

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Introduction: Metastasis represents a major adverse step in the progression of breast carcinoma. Lymph node invasion is the most relevant prognostic factor; however little is known on the molecular events associated with lymph node metastasis process. This study is to investigate the status and role of methylation in lymph node metastatic tumors.Materials and methods: Bisulfite pyrosequencing is used to screen 6 putative tumor suppressor genes (HIN-1, RASSF1A, RIL, CDH13, RARβ2 and E-cadherin) in 38 pairs of primary breast tumors and lymph node metastases.Results: We found that HIN-1, CDH13, RIL, RASSF1A and RARβ2 were frequently methylated both in primary and metastatic tissues (range: 55.3%~89.5%). E-cadherin was not frequently methylated in either setting (range: 18.4%~23.7%). The methylation status of HIN-1, CDH13, RIL, and RARβ2 in lymph nodes metastasis were correlated with that in primary tumors. The Pearson correlation values ranged from 0.624 to 0.472 (p values < 0.01 to 0.001). Interestingly, we observed an association between HIN-1 methylation and hormone status in metastatic lymph nodes. Hypermethylation of HIN-1 in metastasis lymph nodes was significantly associated with expression of ER (odds ratio, 1.070; P = 0.024) and with PR (odds ratio, 1.046; P = 0.026).Conclusions: This study suggests that hypermethylation of tumor suppressor genes is extended from primary to metastatic tumors during tumor progression.

Original languageEnglish (US)
Article number378
JournalBMC cancer
Volume10
DOIs
StatePublished - Jul 20 2010

Fingerprint

Tumor Suppressor Genes
Lymph Nodes
Breast Neoplasms
Neoplasm Metastasis
Methylation
Cadherins
Neoplasms
Odds Ratio
Hormones

ASJC Scopus subject areas

  • Genetics
  • Oncology
  • Cancer Research

Cite this

Feng, W., Orlandi, R., Zhao, N., Carcangiu, M. L., Tagliabue, E., Xu, J., ... Yu, Y. (2010). Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers. BMC cancer, 10, [378]. https://doi.org/10.1186/1471-2407-10-378

Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers. / Feng, Weiwei; Orlandi, Rosaria; Zhao, Naiqing; Carcangiu, Maria L.; Tagliabue, Elda; Xu, Jia; Bast, Robert C.; Yu, Yinhua.

In: BMC cancer, Vol. 10, 378, 20.07.2010.

Research output: Contribution to journalArticle

Feng, Weiwei ; Orlandi, Rosaria ; Zhao, Naiqing ; Carcangiu, Maria L. ; Tagliabue, Elda ; Xu, Jia ; Bast, Robert C. ; Yu, Yinhua. / Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers. In: BMC cancer. 2010 ; Vol. 10.
@article{8a2fbee611344cb68bf5ba6a560647b3,
title = "Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers",
abstract = "Introduction: Metastasis represents a major adverse step in the progression of breast carcinoma. Lymph node invasion is the most relevant prognostic factor; however little is known on the molecular events associated with lymph node metastasis process. This study is to investigate the status and role of methylation in lymph node metastatic tumors.Materials and methods: Bisulfite pyrosequencing is used to screen 6 putative tumor suppressor genes (HIN-1, RASSF1A, RIL, CDH13, RARβ2 and E-cadherin) in 38 pairs of primary breast tumors and lymph node metastases.Results: We found that HIN-1, CDH13, RIL, RASSF1A and RARβ2 were frequently methylated both in primary and metastatic tissues (range: 55.3{\%}~89.5{\%}). E-cadherin was not frequently methylated in either setting (range: 18.4{\%}~23.7{\%}). The methylation status of HIN-1, CDH13, RIL, and RARβ2 in lymph nodes metastasis were correlated with that in primary tumors. The Pearson correlation values ranged from 0.624 to 0.472 (p values < 0.01 to 0.001). Interestingly, we observed an association between HIN-1 methylation and hormone status in metastatic lymph nodes. Hypermethylation of HIN-1 in metastasis lymph nodes was significantly associated with expression of ER (odds ratio, 1.070; P = 0.024) and with PR (odds ratio, 1.046; P = 0.026).Conclusions: This study suggests that hypermethylation of tumor suppressor genes is extended from primary to metastatic tumors during tumor progression.",
author = "Weiwei Feng and Rosaria Orlandi and Naiqing Zhao and Carcangiu, {Maria L.} and Elda Tagliabue and Jia Xu and Bast, {Robert C.} and Yinhua Yu",
year = "2010",
month = "7",
day = "20",
doi = "10.1186/1471-2407-10-378",
language = "English (US)",
volume = "10",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers

AU - Feng, Weiwei

AU - Orlandi, Rosaria

AU - Zhao, Naiqing

AU - Carcangiu, Maria L.

AU - Tagliabue, Elda

AU - Xu, Jia

AU - Bast, Robert C.

AU - Yu, Yinhua

PY - 2010/7/20

Y1 - 2010/7/20

N2 - Introduction: Metastasis represents a major adverse step in the progression of breast carcinoma. Lymph node invasion is the most relevant prognostic factor; however little is known on the molecular events associated with lymph node metastasis process. This study is to investigate the status and role of methylation in lymph node metastatic tumors.Materials and methods: Bisulfite pyrosequencing is used to screen 6 putative tumor suppressor genes (HIN-1, RASSF1A, RIL, CDH13, RARβ2 and E-cadherin) in 38 pairs of primary breast tumors and lymph node metastases.Results: We found that HIN-1, CDH13, RIL, RASSF1A and RARβ2 were frequently methylated both in primary and metastatic tissues (range: 55.3%~89.5%). E-cadherin was not frequently methylated in either setting (range: 18.4%~23.7%). The methylation status of HIN-1, CDH13, RIL, and RARβ2 in lymph nodes metastasis were correlated with that in primary tumors. The Pearson correlation values ranged from 0.624 to 0.472 (p values < 0.01 to 0.001). Interestingly, we observed an association between HIN-1 methylation and hormone status in metastatic lymph nodes. Hypermethylation of HIN-1 in metastasis lymph nodes was significantly associated with expression of ER (odds ratio, 1.070; P = 0.024) and with PR (odds ratio, 1.046; P = 0.026).Conclusions: This study suggests that hypermethylation of tumor suppressor genes is extended from primary to metastatic tumors during tumor progression.

AB - Introduction: Metastasis represents a major adverse step in the progression of breast carcinoma. Lymph node invasion is the most relevant prognostic factor; however little is known on the molecular events associated with lymph node metastasis process. This study is to investigate the status and role of methylation in lymph node metastatic tumors.Materials and methods: Bisulfite pyrosequencing is used to screen 6 putative tumor suppressor genes (HIN-1, RASSF1A, RIL, CDH13, RARβ2 and E-cadherin) in 38 pairs of primary breast tumors and lymph node metastases.Results: We found that HIN-1, CDH13, RIL, RASSF1A and RARβ2 were frequently methylated both in primary and metastatic tissues (range: 55.3%~89.5%). E-cadherin was not frequently methylated in either setting (range: 18.4%~23.7%). The methylation status of HIN-1, CDH13, RIL, and RARβ2 in lymph nodes metastasis were correlated with that in primary tumors. The Pearson correlation values ranged from 0.624 to 0.472 (p values < 0.01 to 0.001). Interestingly, we observed an association between HIN-1 methylation and hormone status in metastatic lymph nodes. Hypermethylation of HIN-1 in metastasis lymph nodes was significantly associated with expression of ER (odds ratio, 1.070; P = 0.024) and with PR (odds ratio, 1.046; P = 0.026).Conclusions: This study suggests that hypermethylation of tumor suppressor genes is extended from primary to metastatic tumors during tumor progression.

UR - http://www.scopus.com/inward/record.url?scp=77954687365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954687365&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-10-378

DO - 10.1186/1471-2407-10-378

M3 - Article

C2 - 20642860

AN - SCOPUS:77954687365

VL - 10

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 378

ER -